Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed on tyrosine kinase inhibitors and immune checkpoint inhibitors. The trial explores PSMA-targeted radioligand therapy as a novel approach, assessing objective response rate, progression-free survival, overall survival, and safety. RENALUT leverages PSMA expression in tumor neovasculature to offer a potential new treatment option for this heavily pretreated population, with imaging-guided therapy and additional cycles for responders. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
